Efficient lentiviral transduction method to gene modify cord blood CD8⁺ T cells for cancer therapy applications.

ABSTRACT: Adoptive T cell therapy utilizing tumor-specific autologous T cells has shown promising results for cancer treatment. However, the limited numbers of autologous tumor-associated antigen (TAA)-specific T cells and the functional aberrancies, due to disease progression or treatment, remain factors that may significantly limit the success of the therapy. The use of allogeneic T cells, such as umbilical cord blood (CB) derived, overcomes these issues but requires gene modification to induce a robust and specific anti-tumor effect. CB T cells are readily available in CB banks and show low toxicity, high proliferation rates, and increased anti-leukemic effect upon transfer. However, the combination of anti-tumor gene modification and preservation of advantageous immunological traits of CB T cell

SUBMITTER: Lo Presti V 

PROVIDER: S-EPMC8056177 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature